Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
DATO-BASE trial: what clinicians have said so far
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- NCT06176261 ↗
- Recruiting
- Nancy Lin, MD
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on DATO-BASE (datopotamab deruxtecan) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DATO-BASE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 16 posts on X | |
| 4 YouTube videos | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer
- Interventions
- Datopotamab Deruxtecan
- Arms
- Cohort A: Estrogen Receptor Positive HER2-Negative Metastatic Breast Cancer · Experimental
- Cohort B: Metastatic Triple-Negative Breast Cancer · Experimental
- Cohort C: HER2-Negative Metastatic Breast Cancer (any ER Expression) with Leptomeningeal Metastases · Experimental
- Enrollment
- 58 (estimated)
- Primary outcomes
- Objective Response Rate (ORR) in RANO-BM Criteria
- Sponsor
- Nancy Lin, MD with Daiichi Sankyo
- Start
- Jan 8, 2024
- Primary completion
- Jan 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06176261 · updated Aug 6, 2026